This is a summary of the European public assessment report (EPAR) for Adynovi. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Adynovi. For practical information about using Adynovi, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Treatment and prophylaxis of bleeding in patients 12 years and above with haemophilia A (congenital factor VIII deficiency).
Therapeutic Area (MeSH)
N/AATC Code
B02BD02
ATC Item
coagulation factor VIII
Pharmacotherapeutic Group
Antihemorrhagics
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| rurioctocog alfa pegol | N/A | Rurioctocog alfa pegol |
EMA Name
Adynovi
Medicine Name
Adynovi
Aliases
N/ANo risk management plan link.
